Fractyl Health, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Financial statements are unaudited and prepared under U.S. GAAP. Fractyl is a clinical-stage metabolic therapeutics company; its lead candidate, Revita, is being studied for type 2 diabetes, and Rejuva is a preclinical gene-therapy platform. Revita has a CE mark in Europe and Germany reimbursement authorization, but the company has no products approved for sale in the United States.
Financial highlights
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $33,000 | $5,000 |
| Gross profit | $14,000 | $2,000 |
| Research and development expense | $14.424 million | $9.349 million |
| Selling, general and administrative expense | $7.132 million | $2.760 million |
| Operating loss | $21.542 million | $12.107 million |
| Net loss | $3.322 million | $11.932 million |
| Net loss attributable to common stockholders | $5.059 million | $16.168 million |
| Net cash used in operating activities | $11.711 million | $9.550 million |
- Revenue and cost of goods sold came from the limited Germany pilot launch. Revenue remains immaterial relative to operating costs.
- Cash and cash equivalents were $121.441 million at March 31, 2024, versus $33.209 million at year-end 2023. Cash, cash equivalents and restricted cash totaled $126.011 million.
- Current assets were $124.472 million and current liabilities $13.272 million. Total liabilities were $79.341 million; these include $28.695 million of long-term notes payable and $31.838 million of operating lease liabilities.
- IPO financing generated approximately $100.3 million in net proceeds, including the partial exercise of the underwriters’ option. Financing cash flow was $101.002 million.
- Q1 net loss was substantially lower than the prior year despite a larger operating loss, principally because of noncash gains from changes in the fair value of notes and warrant liabilities. The reported $18.220 million of other income included $10.446 million from warrant remeasurement and $6.686 million from notes payable; these gains are not operating cash inflows.
Material changes versus Q1 2023
- Operating expenses increased 78% to $21.556 million. R&D rose 54%, mainly from progress on the Revitalize-1 clinical study, increased personnel and facility costs. SG&A increased 158%, including higher stock-based compensation and public-company costs.
- Operating cash use increased to $11.711 million from $9.550 million. Capital expenditures also increased to $1.059 million from $20,000, primarily for office and laboratory improvements.
- IPO completion converted all preferred shares into common stock and converted the 2022 Convertible Notes into common shares. Common shares outstanding at March 31 were 47,896,908; approximately 47.9 million were outstanding as of May 3.
- Accumulated deficit was $349.938 million at quarter-end. Share-based compensation was $5.217 million, compared with $857,000 a year earlier.
Outlook, risks and unusual items
- Management believes the $121.4 million of cash and cash equivalents will fund operating expenses, debt obligations and capital expenditures through 2025. The company expects continued significant losses and negative operating cash flows and says it will need substantial additional capital beyond the IPO proceeds.
- The 2023 Notes carry a floating rate equal to the greater of 5.5% above prime or 13.25%; 6% of interest is payable in kind through September 30, 2024. The notes mature in 2028, with principal payments scheduled to begin in 2026, subject to a possible extension. The company reported compliance with covenants at quarter-end, including a $10 million minimum-liquidity covenant. A further $15 million tranche is conditional on milestones by July 31, 2024; an additional $20 million tranche is uncommitted and subject to lender consent.
- Management reported preliminary Germany registry observations as of April 15, 2024: 33 patients treated, 26 enrolled, and interim follow-up for 19. The company reported three-month changes in HbA1c, weight and medication use, and six-month observations for 14 patients. These are limited real-world interim data, not results of a completed pivotal study. No device- or procedure-related serious adverse events had been reported to date.
- Key execution risks include successful completion of Revitalize-1 and planned Remain-1, regulatory approval and EU MDR certification, clinical and gene-therapy safety, manufacturing and supplier dependence, reimbursement and market adoption, and access to additional financing. The company also reports that substantially all cash deposits were held at two U.S. financial institutions and exceeded federally insured limits.
- On April 3, 2024, after quarter-end, Fractyl entered a manufacturing services agreement with Forge Biologics to support Rejuva candidate RJVA-001 development and cGMP manufacturing for planned first-in-human studies. The filing reports no material legal proceedings. Management concluded disclosure controls were effective as of March 31, 2024.
Important facts for investors to verify
- Whether Revitalize-1 and Remain-1 progress on the company’s expected timelines and produce results adequate for regulatory submissions.
- Whether the preliminary Germany registry observations are sustained in larger, longer-term follow-up and how they compare with controlled clinical evidence.
- Whether management’s cash runway through 2025 remains achievable as clinical, manufacturing and public-company costs rise, and whether additional financing will be needed sooner.
- The status of the conditional $15 million debt tranche and the financing covenant requiring at least $100 million of qualifying equity proceeds by June 30, 2024.
- The effect of the high-cost, floating-rate debt, lease commitments of $59.8 million, and potential dilution from equity awards, warrants or future capital raises.
- Progress toward EU MDR certification for Revita, U.S. regulatory requirements, and the reimbursement pathway for any future U.S. commercial launch.